TWI654977B - 用於控管噁心及嘔吐之組合物 - Google Patents

用於控管噁心及嘔吐之組合物 Download PDF

Info

Publication number
TWI654977B
TWI654977B TW106104622A TW106104622A TWI654977B TW I654977 B TWI654977 B TW I654977B TW 106104622 A TW106104622 A TW 106104622A TW 106104622 A TW106104622 A TW 106104622A TW I654977 B TWI654977 B TW I654977B
Authority
TW
Taiwan
Prior art keywords
pyridoxine
pharmaceutically acceptable
release
dosage form
acceptable salt
Prior art date
Application number
TW106104622A
Other languages
English (en)
Chinese (zh)
Other versions
TW201720442A (zh
Inventor
曼儂 維安德克
Manon VRANDERICK
珍路克 聖昂吉
Jean-Luc ST-ONGE
米契爾 加洛
Michele Gallo
艾利克 加維亞斯
Eric Gervais
Original Assignee
達契斯奈股份有限公司
Duchesnay Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50877783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI654977(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 達契斯奈股份有限公司, Duchesnay Inc. filed Critical 達契斯奈股份有限公司
Publication of TW201720442A publication Critical patent/TW201720442A/zh
Application granted granted Critical
Publication of TWI654977B publication Critical patent/TWI654977B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
TW106104622A 2013-07-22 2014-03-13 用於控管噁心及嘔吐之組合物 TWI654977B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361856971P 2013-07-22 2013-07-22
US61/856,971 2013-07-22

Publications (2)

Publication Number Publication Date
TW201720442A TW201720442A (zh) 2017-06-16
TWI654977B true TWI654977B (zh) 2019-04-01

Family

ID=50877783

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106104622A TWI654977B (zh) 2013-07-22 2014-03-13 用於控管噁心及嘔吐之組合物
TW103109070A TWI589292B (zh) 2013-07-22 2014-03-13 用於控管噁心及嘔吐之組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW103109070A TWI589292B (zh) 2013-07-22 2014-03-13 用於控管噁心及嘔吐之組合物

Country Status (28)

Country Link
US (3) US10028941B2 (https=)
EP (1) EP3024466B1 (https=)
JP (1) JP6379194B2 (https=)
KR (1) KR102242391B1 (https=)
CN (1) CN105492013B (https=)
AR (1) AR097023A1 (https=)
AU (1) AU2014295765B2 (https=)
BR (1) BR112016001474A2 (https=)
CA (1) CA2847022C (https=)
CL (1) CL2016000154A1 (https=)
CY (1) CY1120386T1 (https=)
DK (1) DK3024466T3 (https=)
EA (1) EA029690B1 (https=)
ES (1) ES2670619T3 (https=)
HU (1) HUE039131T2 (https=)
IL (1) IL243638B (https=)
MX (1) MX366760B (https=)
MY (1) MY191347A (https=)
NO (1) NO3086669T3 (https=)
NZ (1) NZ716017A (https=)
PL (1) PL3024466T3 (https=)
PT (1) PT3024466T (https=)
SA (1) SA516370443B1 (https=)
SG (1) SG11201600122RA (https=)
TW (2) TWI654977B (https=)
UY (1) UY35674A (https=)
WO (1) WO2015010194A1 (https=)
ZA (1) ZA201600383B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355912B (es) 2012-02-22 2018-05-04 Duchesnay Inc Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.
SG11201600122RA (en) 2013-07-22 2016-02-26 Duchesnay Inc Composition for the management of nausea and vomiting
US9526703B2 (en) 2014-08-29 2016-12-27 Duchesnay Inc. Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
US10244873B2 (en) 2015-10-01 2019-04-02 Isee Store Innovations, Llc Adjustable product display system and method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6340695B1 (en) * 2000-12-20 2002-01-22 Duchesnay Inc. Rapid onset formulation
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8524001D0 (en) 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
US4842867A (en) 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US5110597A (en) 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
NZ242065A (en) 1991-03-26 1996-06-25 Csl Ltd Delayed release implant having a degradable or rupturable polymeric coating
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FR2772615B1 (fr) 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
WO2000059479A1 (en) 1999-04-06 2000-10-12 Pharmaquest Ltd. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
WO2002055058A2 (en) 2001-01-09 2002-07-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
DE60336727D1 (de) 2002-08-16 2011-05-26 Microchips Inc Vorrichtung mit kontrollierter abgabe und verfahren
GB0229725D0 (en) 2002-12-19 2003-01-29 Univ Wales Medicine Haplotype partitioning and growth hormone SNPs
US20100221321A1 (en) 2003-02-27 2010-09-02 Innercap Technologies, Inc. Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions
JP5107041B2 (ja) 2004-09-01 2012-12-26 マイクロチップス・インコーポレーテッド レザバ内容物の制御された放出または曝露のための、マルチキャップレザバデバイス
GB0502475D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
KR101190708B1 (ko) 2010-03-12 2012-10-12 주식회사 대웅제약 모사프리드 또는 이의 염을 포함하는 서방형 약학 조성물
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US8486453B2 (en) 2010-06-22 2013-07-16 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
CA2825917C (en) 2011-02-14 2016-08-30 The Procter & Gamble Company Filmcoated solid dosage forms comprising honey in the coating
CA2835293C (en) 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
MX355912B (es) 2012-02-22 2018-05-04 Duchesnay Inc Formulación de doxilamina y piridoxina y/o sus metabolitos o sales.
WO2013123569A1 (en) 2012-02-22 2013-08-29 Duchesnay Inc. Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
SG11201600122RA (en) 2013-07-22 2016-02-26 Duchesnay Inc Composition for the management of nausea and vomiting

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197329B1 (en) * 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
US6340695B1 (en) * 2000-12-20 2002-01-22 Duchesnay Inc. Rapid onset formulation
US7704542B2 (en) * 2001-09-12 2010-04-27 Xanodyne Pharmaceuticals, Inc. Vitamin/mineral compositions with DHA

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Can J Clin Pharmacol Vol 16 (3) Fall 2009:e400- e406; October 29, 2009全文
CAN J CLIN PHARMACOL, vol. 16, no. 3, 29 October 2009 (2009-10-29), pages e400 - e406 *

Also Published As

Publication number Publication date
CA2847022A1 (en) 2014-06-03
NZ716017A (en) 2020-07-31
AU2014295765A1 (en) 2016-02-04
AR097023A1 (es) 2016-02-10
MX366760B (es) 2019-07-23
UY35674A (es) 2014-12-31
HUE039131T2 (hu) 2018-12-28
US10028941B2 (en) 2018-07-24
NO3086669T3 (https=) 2018-06-23
CA2847022C (en) 2015-04-07
EP3024466A4 (en) 2017-03-29
WO2015010194A1 (en) 2015-01-29
HK1218264A1 (en) 2017-02-10
JP2016527237A (ja) 2016-09-08
US9439920B2 (en) 2016-09-13
EP3024466B1 (en) 2018-04-04
TW201720442A (zh) 2017-06-16
EA029690B1 (ru) 2018-04-30
CY1120386T1 (el) 2019-07-10
SG11201600122RA (en) 2016-02-26
US20150025033A1 (en) 2015-01-22
ES2670619T3 (es) 2018-05-31
US20150025032A1 (en) 2015-01-22
JP6379194B2 (ja) 2018-08-22
BR112016001474A2 (pt) 2020-04-14
KR20160033201A (ko) 2016-03-25
IL243638A0 (en) 2016-02-29
EP3024466A1 (en) 2016-06-01
PT3024466T (pt) 2018-07-13
MY191347A (en) 2022-06-17
CN105492013B (zh) 2018-09-18
US9452181B2 (en) 2016-09-27
MX2016000884A (es) 2016-05-05
CL2016000154A1 (es) 2016-08-05
AU2014295765B2 (en) 2019-02-14
KR102242391B1 (ko) 2021-04-21
DK3024466T3 (en) 2018-06-06
US20160143892A1 (en) 2016-05-26
IL243638B (en) 2019-09-26
ZA201600383B (en) 2017-11-29
SA516370443B1 (ar) 2018-08-08
EA201690149A1 (ru) 2016-06-30
TWI589292B (zh) 2017-07-01
TW201513860A (zh) 2015-04-16
PL3024466T3 (pl) 2018-08-31
CN105492013A (zh) 2016-04-13

Similar Documents

Publication Publication Date Title
TWI638657B (zh) 多西拉敏及吡哆醇及／或其代謝物或鹽之調配物
WO2013123569A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
TWI654977B (zh) 用於控管噁心及嘔吐之組合物
HK1218264B (en) Composition for the management of nausea and vomiting
HK1247571B (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
HK1247571A1 (en) Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees